Our findings demonstrate that SOX9 overexpression alleviates hepatic lipid accumulation in MASH by activating the AMPK pathway. These results highlight SOX9 as a promising therapeutic target for ...
Activating the PPARβ/δ-AMPK metabolic pathway could be an effective strategy to tackle the most common chronic liver disease in the world’s population. A study led by Manuel Vázquez Carrera, group ...
Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. The partnership builds on previous efforts targeting AMPK ...
Metabolic dysfunction-associated fatty liver disease (MAFLD), also known as non-alcoholic fatty liver disease (NAFLD), affects over 30% of the global adult population. Characterized by at least 5% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results